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From the Editor’s Desk
This year’s first issue is on Thrombosis and
Haemostasis which is a complex physiological
process occurring in the human body. Most
researchers claim that it is two sides of the same
coin. Bleeding and thrombotic disorders are common
and challenging medical problems. A good bleeding/
haemostatic history will give you the diagnosis
in majority of patients. Laboratory investigations
then support your differential diagnosis. AKUH’s
Clinical Laboratory offers a wide panel of bleeding
and thrombophilia testing that can be effectively
utilized in proper evaluation of the patients with
haemostatic abnormalities. This issue is an attempt to

provide physicians with information on haemostatic
abnormalities that help in screening and diagnosing
of these diseases. The issue includes articles on
appropriate work-up of suspected bleeding disorder,
transfusion-associated-viral infections such as HIV,
hepatitis B and C in patients who require blood
product support for treatment, investigations for
thrombophilia, acquired bleeding disorders such as
paroxysmal nocturnal haemoglobinuria etc. We hope
that our readers will gain in depth insight from this
thematic issue.
Dr Natasha Ali

Critical International Normalised Ratio
Dr Shabneez Malik
Haematology

Oral anticoagulant therapy is commonly used in
the management of venous thrombosis such as
deep venous thrombosis of veins and pulmonary
embolism.
Previously, laboratories used to report
prothrombin time as a part of anticoagulation
monitoring. It was then found out that the
prothrombin time varied due to the difference
in sensitivity of various thromboplastins
used in different clinical laboratories. World
Health Organization (WHO) devised the term
“International Normalised Ratio” (INR) to
reduce this inter-laboratory variability.This term
is self-explanatory. This is a ratio of patient’s
prothrombin time divided by reference normal
prothrombin time to the power of a coefficient
which is known as “international sensitivity
index.” This relates the sensitivity of a given
thromboplastin to the sensitivity of WHO’s
first international reference preparation of
thromboplastin (given an ISI of 1.0).
Monitoring of INR is critical in warfarinised
patients. Because of the narrow therapeutic INR,
patients on warfarin are stabilised within a range
of 2-3. Elevated INR can lead to haemorrhagic

complications on one hand while sub-therapeutic
INR can result in thrombosis. Therefore accurate
monitoring of INR is crucial in preventing
bleeding and thrombosis. The goal of establishing
critical INR is to alert the physician to a
potentially life threatening bleeding or thrombosis
requiring urgent intervention. Critical INR value
needs to be established at local level as the line
between therapeutic and critical INR is thin.
The Seventh American College of Chest Physicians
Conference on Antithrombotic and Thrombolytic
Therapy recommended therapeutic intervention
in oral anticoagulant patients who have an INR
of 5.0 or greater. Therefore, critical INR in many
laboratories is 5.0. In 2000 College of American
Pathologist survey, 166 laboratories (27 per cent)
had chosen a critical INR of 5.0. Similarly an INR
below 1.5 should be considered critical for a patient
on oral anticoagulation as the patient is at risk for
thrombosis.
At AKUH, an INR of 5.0 or above is considered
critical. At this INR, the patient is contacted for
clinical details including medications. Patients are
advised to repeat INR and to consult their primary
physicians on emergency basis.
3
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How to Investigate a Bleeding Disorder?
Dr Natasha Ali
Haematology

Bleeding is a very common symptom for which
patients approach doctors. At the same time,
bleeding disorders are a common reason for a
general practitioner to consult a haematologist.
Determining the cause of bleeding disorders is
challenging due to the variability of symptoms
from patient to patient and requires a stepwise
approach which traces each case from history
to laboratory investigations. Questions usually
focus on three main causes of bleeding: impaired
vascular integrity, thrombocytopenia or platelet
dysfunction and deficiency of clotting factors. The
clinical manifestations of any bleeding disorder
depend on the nature of defect and its severity.

Physical Examination
The underlying cause can be determined by carefully
examining the patients. Usually low platelets or
platelet dysfunction produce muco-cutaneous
bleedings [Fig. 1] while clotting factor deficiency
results in a cavity bleed for example within joints,
abdominal cavity, muscle, etc. [Fig. 2].

History
Table 1. Questions for a Patient Suffering from a Bleeding
Disorder

Onset of bleeding – to distinguish between
hereditary and acquired bleeding disorders

Fig. 1. Petechiae (small pinpoint cutaneous bleeding due to platelet defect
or low platelets)

Type of bleeding – whether it is muco-cutaneous or
within a cavity
Severity of bleeding – patient is asked whether
the symptoms occur spontaneously or during
haemostatic challenge e.g. surgical procedures,
road traffic accidents, etc.
Frequency of bleeding.
Timing of bleeding episode – whether it occurs
immediately or is it delayed.
Are other members in the family affected?
Drug history which particularly includes use of
aspirin or NSAIDS
Nutritional history – deficiency of vitamin C
In case of an infant presenting with bleeding,
ask the parents regarding prolonged bleeding
during child’s circumcision or from his/her
umbilical stalk
4

Fig. 2. Hemarthrosis in a Hemophilia patient – bleeding within the knee
joint secondary to defective coagulation

Laboratory Investigations
Certain pre-requisites should be met before
collection of blood samples for lab tests. These
are listed in Table 2.
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Table 2. Pre-analytic Considerations for Coagulation Testing

Case 2

Patient should not have received recent transfusions
(blood, plasma products and platelets)

If an isolated APTT elevation is observed and the
patient has bleeding tendency then the APTT mixing
test can help to differentiate between factor VIII and
IX deficiency. Factor XI is also a remote possibility
[Fig. 4]. Von Willebrand Disease can lead to raised
APTT with elevated bleeding time. Presence of lupus
anticoagulants or factor XII deficiency can increase
APTT but patient will have no bleeding symptoms in
this case.

Patient should not be on medications like Aspirin,
NSAIDS or antibiotics (penicillin)
Patient should not be in stress (as it increases factor
VIII levels)
Patient should not be pregnant (as it increases Von
Willebrand factor antigen levels and factor VIII)
Screening tests: Any patient with a bleeding disorder
should be tested for basic coagulation profile. The
results of these will determine whether more specific
tests are required for diagnosis. These tests are listed
in Table 3.
Table 3 Screening Test for Investigating Bleeding Disorders

CBC including platelet count and peripheral film
review

PT-N
APTT- #
Platelet-N

Injury related
Mild to moderate Haemophilia A & B
Severe XI deficiency

Unprovoked

Mild bleeding
vWD

Severe bleeding
Severe Haemophilia
Type III vWD

Bleeding time
Prothrombin time [PT]
Activated partial thromboplastin time [APTT]
Urea clot lysis test for factor XIII
Specialised tests: Based upon the screening test results,
second line investigations are ordered for further work
up. Different approaches are used to diagnose a patient
depending on clinical details and screening tests. The
four possible common scenarios are described below:
Case 1
If only PT is prolonged with normal platelet count
and APTT, then factor VII deficiency should be
suspected [Fig. 3]. Factor VII assay will help in
establishing definitive diagnosis.
PT-#
APTT-N
Platelet-N

Bleeding
Severe factor VII
deficiency

No bleeding
Mild factor VII
deficiency, Use of oral
anticoagulants

Fig. 3. Algorithm for Isolated Prolonged PT

Fig. 4. Algorithm for Isolated Prolonged APTT

Case 3
Combined elevation of PT and APTT raises the
possibility of deficiencies of factors in common
pathways such as I, II, V and X. Common causes
are vitamin K deficiency in neonates or infants and
liver disorders in adults. Anticoagulation therapy also
leads to raised PT and APTT [Fig. 5].

PT-#
APTT-#
Platelets-N

Bleeding
Deficiency of common
pathway factors. Combined
factor V&VIII deficiency
Vitamin K deficiency

No bleeding
Mild deficiency of common pathways factors

Fig. 5. Algorithm for Combined Elevation of PT and APTT

5
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Case 4
Profound disturbance of primary screening results
are indicative of global haemostatic abnormalities
such as advanced hepatic disorder or disseminated
intravascular coagulation (DIC) [Fig. 6].
In summary, while investigating a patient for
suspected bleeding disorder, a thorough clinical
history and physical examination is of paramount
importance since majority of the disorders can
be diagnosed with these two tools. Additionally,
appropriate laboratory testing and timely
consultation with a haematologist experienced in

PT-#
APTT-#
Platelets-

Bleeding
DIC Liver disease
Lupus anticoagulants

No bleeding
Same causes

Fig. 6. Algorithm for Eelevation of all Primary Screening Investigations.

dealing with bleeding disorders are the key features
of successful management of these patients.

Nucleic Acid Testing at AKUH
Sana Chundrigar
Molecular Pathology

In recent years, despite improvements in serological
tests for HCV, HBV and HIV infections, instances of
viral transmission via transfusion still occur because
of donations that take place while a donor is either
in the pre-seroconversion window phase, infected
with immunovariant viruses, or a non-seroconverting
chronic carrier.
What is Nucleic Acid Testing and how does it help?
Nucleic Acid Testing, (NAT) is a highly sensitive
molecular method of testing blood donations for
viral nucleic acid. It is used to detect low level of
viral genetic material present in the blood specimen
even before the body begins producing antibodies in
response to the virus.
Detection of HIV I and II
11 days

25 days

Detection of HCV
12 days
Detection of HBV
25 days

75 days
60 days

NAT testing
Ag & Ab Detection
Fig. 1. Window period of HIV, HCV and HBV

6

NAT significantly reduces the ‘window period,’
which is the time between donor exposure to the
virus and the appearance of antibodies [Fig 1]. By
reducing the window period it further diminishes
occurrence of disease transmission via transfusion.
The performance of the NAT assay is essentially
dependent on both its analytical and clinical
sensitivity and specificity. The analytical sensitivity
is generally determined by testing dilutions of
standardised materials such as WHO International
Standards and subsequent calculations of 95 per
cent Limit of Detection (LOD). A NAT can be
conveniently performed on a mini-pool which is a
pool of six test samples.
Countries that have introduced NAT have
encountered a decrease in residual risk of viral
transmissions. Although other safety measures such
as more stringent selection of blood donors have
contributed as well as a marked decrease is evident
between pre- and post-NAT implementation. The
residual risk for HCV transmission prior to NAT
was 0.64 cases per million in France and 3.94 per
million in Spain which decreased to 0.1 per million
and 2.33 per million respectively after NAT was
adopted. HIV NAT yield rates were estimated at
0.3 per million donations in France and Spain as
opposed to 0.59 and 2.48 respectively preceding
NAT incorporation. There is potential that next
generation NAT testing could completely eradicate
transfusion risk of HIV, HCV and HBV.
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NAT at AKUH
The quality of blood products at the AKUH has further
improved by the recent addition of NAT testing in the
blood donor screening programme. There is automated
pooling of blood donations, sample preparation,
amplification (real time polymerase chain reaction or
PCR) and detection. [Fig.2].
1. Lysis, stabilisation
and deproteination

2. Capture		

3. Wash			

Real time data collection allows monitoring of
the PCR process in each individual cycle instead
of end point measurement after completion of all
cycles [Fig.3].

4. Elute

Fig. 2. Steps in Nucleic Acid Extraction

Before authorising for general use the NAT
test was validated on more than 1000 blood
donations. So far up to 18,000 blood donations
have been screened by NAT assay and
unsurprisingly it has captured many window
period positive specimens.

Fig. 3. Principles of the Real Time PCR

Lab Diagnosis of von Willebrand Disease
Bushra Afaq and Dr Bushra Moiz
Haematology

Von Willebrand Disease (VWD) is an autosomally
inherited congenital bleeding disorder resulting
from deficiency or dysfunction of von Willebrand
factor (VWF). The predominant clinical problems
are muco-cutaneous bleeds. Therefore, patients
usually present with petechiae, oral and gum
bleeding, nose bleeding or epistaxis. Excessive
menstrual loss or menorrhagia is a common
bleeding problem in women of reproductive
age. Circumcision acts as a good haemostatic
challenge in case of males and therefore boys may
be diagnosed earlier than girls. VWD has three
clinical types based on von Willebrand Antigen
(VWAg) levels.
Laboratory assessment for Von Willebrand Disease
Following are the laboratory tests which should be
performed for the laboratory diagnosis of VWD.

Bleeding time: It is performed by IVY method. Its 		
reference range is between 1-6 minutes
APTT: A clotting assay having a reference range
between 25-35 seconds.
VWAg: A quantitative determination of von
Willebrand activity by turbidimetric method. Its
reference range is between 50-160 per cent.
F-VIII: A clotting assay having a reference range
between 50-150 per cent.
R-COF: A quantitative determination of F-VIII
Ristocetin Cofactor activity using aggregometry
technique. Its reference value is >40 per cent.
RIPA: Ristocetin platelet induced aggregometry.
Normal platelets show response to standard strength
of ristocetin but fail to respond to a lower dose.
7
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Results of the above stated laboratory tests are summarized in the Table 1.
Table 1. Expected Laboratory Values in Subtypes of VWD
Normal

Type 1

Type
2A

Type
2B

Type
2M

Type
2N

Type 3

VWF:Ag

N

L or 

or L

or L

or L

N or L

absent

or L

VWF:RCo

N

L or 







N or L

absent



FVIII

N

N or 

N or 

N or 

N or 



1-9 IU/dL

N or L

RIPA

N

often N



often N



N

absent

often N

BT

N

N or #

#

#

N

N

#

#

Platelet
Count

N

N

N

N or 

N

N

N





Decreased activity in comparison to reference range

#

More than normal range

PLTVWD

N Normal
L

Subnormal activity

AKUH’s Clinical laboatory offers a variety of tests required for diagnosis and characterisation of VWD.

Scoring Systems in Diagnosis of Disseminated
Intravascular Coagulation
Dr Natasha Ali
Haematology

The liver is the most important organ involved
in the regulation of haemostasis. Most of the
clotting factors, their inhibitors and a number of
proteins responsible for fibrinolysis are produced
in the liver. Therefore, liver disease impacts both
primary and secondary haemostasis pathways
through a number of different mechanisms.
Abnormalities of the clotting cascade are the
predominant features of acute and chronic liver
disease. In some patients suffering from hepatic
disease, physicians are faced with the diagnostic
challenge of an underlying bleeding or thrombotic
diathesis due to overlap between various clinical
syndromes including Disseminated Intravascular
Coagulation (DIC).
8

According to the International Society of Thrombosis
and Haemostasis (ISTH), DIC is a syndrome
characterised by a systemic intravascular activation
of coagulation, with loss of localisation, arising from
different causes. It can originate from and cause
damage to the microvasculature, which if sufficiently
severe can produce organ dysfunction. ISTH also
proposed that the working definition of DIC can be
divided into two phases:
a)

Non-overt DIC: represents subtle haemostatic
dysfunction

b) Overt DIC: de-compensated phase of non-overt
DIC
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Events responsible for DIC in liver disease include
liver necrosis, impaired endotoxin clearance,
surgery, shock and ascites recirculation. DIC can
be recognised as a syndrome suggested by clinical
signs and laboratory tests. The characteristic
laboratory findings include: prolonged prothrombin
time (PT), activated partial thromboplastin time
(APTT), thrombin time (TT), increased levels of
fibrin related markers (fibrin degradation products,
D-Dimer), decreased platelet count, fibrinogen level,
plasma coagulation factors and their inhibitors. More
specialised and useful tests include: prothrombin
activation fragments and thrombin-antithrombin
complex (TAT).
In 2001, ISTH proposed two separate scoring
systems for overt and non-overt DIC. The overt
DIC score consists of a five steps diagnostic
algorithm, in which a specific score, reflecting the
severity of the abnormality found, is given to each
of the laboratory tests [Table 1]. A score of five or
Table 1. ISTH Score System for Overt DIC
Screening Tests
PLATELET COUNT

Findings
Points
>100,000/µL		 0
50,000-100,000/ µL		 1
<50,000/ µL		 2
PROTHROMBIN
(PT upper limit of reference
TIME
range) >3 secs		 0
(PT upper limit of reference range)
=3-5.9 secs		 1
(PT upper limit of reference range)
≥6 secs		 2
FIBRINOGEN
>100mg/dl		0
<100mg/dl		1
FIBRIN MONOMER No increase		 0
Moderate increase		 2
Severe increase		 3

more is considered to be compatible with DIC,
whereas a score of
less than five may be indicative (but not
affirmative) for non-overt DIC. Similarly using
certain clinical and laboratory findings [Table
2] a score of five or greater is compatible with
Table 2. ISTH Score for non-Overt DIC
Parameter
Diagnosis

Findings
Points
Not associated with DIC		
0
Associated with DIC		 2
Platelet count
>100,000/µL		0
<100,000/µL		1
Prolongation of PT
< 3 seconds		 0
> 3 seconds		
1
Soluble fibrin or FDP Normal		0
Increased		1
Antithrombin III
Normal
-1
Low		1
Protein C
Normal
-1
Low		1

non-overt DIC and could diagnostically define
patients with a poor prognosis due to haemostatic
dysfunction, independent of developing overt
DIC.
Following steps are suggested for the diagnosis
of DIC:
Step 1: Determine if the patient has an underlying
condition associated with DIC. If no underlying is
present then do not proceed further.
Step 2: Order screening coagulation tests and
decide whether patient has overt or non-overt
DIC.

9
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Ristocetin Cofactor Activity
Bushra Afaq
Haematology

Ristocetin Cofactor (RCo) measurement is essential
for the diagnosis of von Willebrand disease (VWD).
VWD is an autosomally-inherited congenital
bleeding disorder that is caused by deficiency or
dysfunction of von Willebrand factor (VWF), a
plasma protein that mediates the initial adhesion
of platelets at site of vascular injury and also binds
and stabilises blood clotting factor VIII (FVIII)
in the circulation. Therefore, defects in VWF can
cause bleeding by impairing platelet adhesion or by
reducing the concentration of FVIII.

plasma is then tested in the presence of Ristocetin
and reconstituted platelets and an aggregation
pattern is determined. RCo Activity of test plasma is
interpolated from the standard curve [Fig. 1].

VWD is classified into three major categories:
1. Type 1: a quantitative deficiency of VW
factor (<30 per cent)
2. Type 2: a qualitative defect of VWF having
dysfunctional proteins. Type 2 has further
subtypes (2A, 2B, 2M, 2N) based on 		
laboratory tests.
3. Type 3: a severe deficiency of VWF (<3 per cent)
The RCo Assay is used in the quantitative
determination of RCo activity in citrated plasma.
It is particularly useful in detection of type 2A,
2B, and 2M VWD, where the VWF: Ag may be
normal or near normal whereas the VWF: RCo is
markedly reduced.
RCo Activity in plasma may be determined by
the agglutination of a standardised suspension of
platelets in the presence of von Willebrand factor
using the antibiotic called Ristocetin. The RCo
Activity is the in-vitro activity of the von Willebrand
factor, which is responsible for the agglutination
of platelets in the presence of Ristocetin. Levels of
RCo activity are determined by the ability of the test
plasma and Ristocetin to induce aggregation in a
standardised platelet suspension.
Principle of the test method is reconstituted
lyophilised platelets are treated with Ristocetin in the
presence of varying dilutions of normal standardised
human plasma having known amounts of RCo
Activity. A standard curve is thus prepared. Patient
10

Fig. 1. Standard Curve and Interpolation of Ristocetin Cofactor Activity for the Patient

Results of less than 40 per cent RCo (von
Willebrand Factor) are generally considered
abnormal and are indicative of von Willebrand
disease.
As a quality control of deficient von Willebrand
Reference Plasma is included in the test kit to
function as an abnormal Control. The RCo value of
this Control is less than 30 per cent.
The RCo assay is considered by many investigators
to be the single most important assay for VWD.
However, a complete diagnosis and determination
of the variant forms of this coagulopathy requires an
evaluation of family history and lab parameters such
as Von Willebrand antigen, Factor VIII activity and
bleeding time.
The test is available at Aga Khan University
Hospital’s clinical laboratory.
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All You Need to Know About Thrombophilia
Screening
Dr Bushra Moiz
Haematology

What is Thrombophilia?

Selection of Patient for Heritable Thrombophilia

Heritable thrombophilia is an increased tendency
towards venous thrombosis. Initially the terminology
was reserved for inherited disorders only but later
the term ‘thrombophilia’ was used loosely for both
inherited and acquired disorders with a predisposition
for either venous or arterial thrombosis.

The inherited thrombophilia screening in an unselected
patient population is not advisable. Since it is genetic,
testing with personal and family considerations
therefore patients should be carefully chosen. Not every
patient with thrombosis requires this testing. Table 2
and 3 summarise the conditions in which screening
should not be performed. The information provided
is according to the guidelines published by the British
Committee of Standards in Haematology.

Assessment of Thrombophilia
1. Clinical: Assessment of thrombophilia starts
with detailed clinical history and physical
examination. The patient should be assessed
for acquired risk factors, medication and comorbids.
2. Laboratory: The tests are listed in Table 1.
All the mentioned tests are offered by the
clinical laboratory at AKUH.

What are the Appropriate Timings of Testing?
There is seldom any point in striving to obtain
samples for thrombophilia testing when the patient
presents with deep venous thrombosis (DVT)
or pulmonary embolism (PE). During an acute
thrombotic episode, patients usually have low levels
of protein C, protein S and antithrombin III

Table 1. Comprehensive Panel of Thrombophilia Testing

Test
Routine

Specialised

Ancillary

Purpose

CBC, PT, APTT, Liver function tests
and Serum creatinine

To determine safety profile before initiation of
heparin and warfarin

Protein C, protein S, anti-thrombin III,
activated protein C resistance(APCR)

Required in investigation of heritable
thrombophilia

Anticardiolipin antibodies (IgM and
IgGO), lupus anticoagulants,
serum homocysteine levels

Required in acquired thrombophilia

PNH screening (CD55and 59)

Required for suspected PNH (intravascular
haemolysis and pancytopenia)

HIT

For suspected HIT (heparin induced
thrombocytopenia)
Needed for suspected TTP (micro-angiopathic
haemolytic anaemia, thrombocytopenia, renal
insufficiency and neurological deficit)

ADMATS-13 assay
JAK-2 V617F mutation

For suspected myeloproliferative disorder (MPD)
with erythrocytosis/leucocytosis/thrombocytosis

11
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Table 2. Conditions Recommended for Thrombophilia Screening

Venous thrombosis at an early age ( <40 years)
Venous thrombosis in a patient with thrombosis prone family ( >2 symptomatic family members)
Neonates and children with fulminating purpura (purpura fulminans) for protein C and S
Adults with skin necrosis following warfarin therapy for protein C and S
Case finding of asymptomatic relatives for high risk such as protein C and S deficiencies in thrombosis
prone families
Women requiring contraceptives or hormone replacement therapy with high risk thrombophilia in symptomatic relative
Pregnancy with previous travel related thrombosis
Asymptomatic pregnant woman with family history of thrombosis which was either unprovoked or provoked
by pregnancy, combined oral contraceptives (COC) exposure or traveling

Table 3. Conditions Which Should not be Tested for Heritable Thrombophilia

Unselected patients with first episode of thrombosis
First episode of cerebral venous thrombosis
Arterial thrombosis
Paediatric stroke
Hospital acquired venous thrombosis
Asymptomatic relatives of low risk thrombophilia (factor V Leiden, prothrombin gene mutation).
Retinal vein occlusion
First event of an intra-abdominal vein thrombosis
Pregnant women with previous unprovoked thrombosis
Pregnancy with previous trauma/surgery related thrombotic event
Pregnancy or COC related thrombosis
Unselected patients with upper limb thrombosis
Central Venous Catheters related thrombosis

12
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as the two are consumed in an attempt to natural
thrombolysis. This results in false low levels
of these proteins. Testing should be delayed
for at least one month after discontinuation of
oral anticoagulation. Pregnancy and oestrogen
reduce protein S levels significantly and increase
resistance to APC. If possible, thrombophilia
testing should be avoided in inter-current illnesses,
pregnancy and with oral contraceptive usage.

How should I Interpret the Tests?

How should I collect Blood Samples?

Do I need Repeating the Tests?

The blood sample should be collected in standard
sodium citrate bottle/blue top vacutainer in a ratio
of 9:1 for lupus anticoagulant, protein C, S, APC,
and AT-III. EDTA blood sample is required for HIT,
PNH and JAK-2. Clotted blood sample is needed for
anticardiolipin antibodies and homocysteine.

Repeat testing for protein C, S and anti-thrombin III
is indicated and a low level should be confirmed on
one or more separate samples. Diagnosis of deficiency
should not be made on a single abnormal test.

Methodology assays used at AKUH Clinical
Laboratory

Initiation and intensity of anticoagulation
following diagnosis of acute venous thrombosis
in a patient should be the same with or without
thrombophilia. Testing of thrombophilia in
selected patients with strong family history of
unprovoked thrombosis may influence decision
regarding duration of anticoagulation.

The thrombophilia screening should be supervised
by experienced laboratory staff and the clinical
significance should be made in consultation with an
experience haematologist who is aware of relevant
factors that may affect test results in each case. The
factors affecting thrombophilia testing resulting in
spurious assessment is listed in Table 5.

Would the Testing affect Patient Management?

At AKUH, functional assays are used for heritable
thrombophilia which have acceptable accuracy and
precision. Table 4 shows the various tests and their
methodologies used at AKUH.

Table 4. Tests and their Methodologies Used at AKUH Clinical Laboratories

Clinical utility

Method

Tests
Protein C

Chromogenic assay

Protein S

Clotting based assay

Antithrombin III

Chromogenic assay

APCR
Lupus anticoagulant

Clotting based assay

Anticardiolipin antibodies

ELISA

Serum homocysteine

Immunogenic microparticulate
assay

PNH

PNH screening

Gel immunoassay

HIT

HIT screening

Gel immunoassay

TTP
MPD

ADAMTS-13
JAK-2 V 617 F

ELISA
PCR

Heritable thrombophilia

Acquired thrombophilia

Clotting based assay

13

VOL. 44, ISSUE 1

JULY 2018
Table 5. Conditions Giving Rise to Misleading Results in Thrombophilia Screening

Acute thrombosis
Anticoagulants- heparin and warfarin
Direct thrombin inhibitors e.g. argatroban, lepirudin, bivalirudin
Liver disease
Pregnancy and COC

Utility of ADAMTS-13 Assay
Dr Farheen Karim Mahar
Haematology

A Disintegrin and Metalloprotease with
Thrombospondin Type 1 Motif, 13 (ADAMTS-13)
is an enzyme which is released primarily from the
stellate cells of the liver but is also found in platelets
and endothelial cells. It is involved in the regulation
of the size of von Willebrand factor (VWF) in
plasma.
ADAMTS-13 maintains primary haemostasis by
proteolysing ultra-large von Willebrand Factor
(ULvWF). The latter is the hyperactive form of
vWF which is released from storage granules
(Weibel-Palade bodies) of endothelial cells in
response to inflammatory stimulation. The ULvWF
has more affinity for platelets favouring platelet
aggregation at sites of high shear stress with
subsequent formation of micro vascular thrombi. The
ULvWF relies upon ADAMTS-13 for its cleavage
and its conversion into a less active form.
Deficiency of ADAMTS-13 may be congenital
(Upshaw-Schulman syndrome) or more often
than not acquired. An acquired deficiency is
attributed to the presence of auto-antibodies
against ADAMTS-13 which may either inhibit
ADAMTS-13 function or may cause rapid
clearance of circulating ADAMTS-13. Inherited
or acquired deficiency of ADAMTS-13 impairs
ULvWF cleavage. Deficient proteolysis of ULvWF
results in disseminated platelet-rich thrombi in
the microcirculation which in turn cause typical
thrombotic micro-angiopathies resulting in end
organ ischemia.
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The laboratory assessment of ADAMTS-13 levels
is useful since severe deficiency of ADAMTS-13
has been proposed as a specific laboratory marker
of thrombotic thrombocytopenic purpura (TTP)
or Upshaw-Schulman syndrome. It is also seen in
conditions like sepsis, disseminated intravascular
coagulation (DIC) and metastatic malignancy.
Mild to moderate deficiency is seen in chronic
inflammation, hepatic dysfunction and pregnancy.
Given that severe secondary deficiency of
ADAMTS-13 might correlate with development of
widespread microvascular thrombi and end organ
injury, determination of ADAMTS-13 activity at
the time of hospital admission in patients with
severe conditions like sepsis and DIC will
help in understanding the extent of the disease.
It also raises the possibility of novel supportive
therapies for patients with sepsis and DIC such as
ADAMTS-13 supplementation and plasma therapy
because sepsis may have the same pathophysiology
of severe ADAMTS-13 deficiency for thrombotic
microangiopathies as idiopathic TTP.
The test is currently offered by clinical
laboratories of AKUH. It is based on the principle
of enzyne linked immuno sorvent assay (ELISA)
technique. Two to three millilitres of blood
collected in citrate anticoagulant is required for
the test. The reference range developed at AKUH
for ADAMTS-13 is 175-365 ng/dl. There is no
difference in reference range between males and
females or adults and children.
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Homocysteine as a Risk Factor of Thrombosis
Rakhshanda Maher
Chemical Pathology

Elevated plasma homocysteine is associated with
increased incidences of cardiovascular mortality,
stroke, dementia and Alzheimer’s disease, bone
fracture and higher prevalence of chronic heart
failure. It was also shown that elevated plasma
homocysteine is a risk factor for preclampsia and
neural tube defects (NTD). Homocysteine has been
implicated in atherosclerotic and thrombotic vascular
disease in the general and in end-stage renal disease
(ESRD) population as well.
Homocysteine is a sulphur containing amino acid,
formed normally during metabolism of another
sulphur containing amino acid methionine. It is
metabolised by pathways, remethylation and transsulfuration of methionine (Fig 1). Approximately 50

An elevated plasma homocysteine level has been
found in patients with thrombotic disorders. In actual
thrombosis is a formation of blood clot inside the
blood vessel, obstructing the blood flow through the
circulating system. It is mainly classified into venous
and arterial thrombosis. The mechanism by which
homocysteine contributes to atherothrombosis is
complex and in vivo relevance is uncertain. However
in the Journal of Clinical Investigation-2009,
Jacoviner and his colleagues have reported a unique
mechanism in vivo by which homocysteine may
contribute to vascular disease. Accordingly, there is
impairment in the synthesis of endothelial surface
plasminogen which is the major fibrinolytic agent.
This leads to micro vascular dysfunction and
subsequent macro vascular occlusion in individuals
with hyperhomocystenemia.
Most studies so far have indicated normal
plasma homocystiene level to be in the
range of 5 to 15 ul/L. However this does not
imply that there is no risk associated with
homocystiene levels between 10 to 15µl/L.

Fig. 1. Metabolism of Homocysteine

per cent of methionine is metabolised to cystathioinine
by cystathionine beta synthesase (CBS). This is
a one way reaction that permanently removes
homocysteine from the methionine cycle and initiates
the transsulfuration pathway for methyl group either
from N5 mehyltetrahydrofolate (in all tissues) or from
betaine (in liver and kidneys) to form methionine. The
former methylation step requires folate and vitamin
B12 as cofactors in trans-sulfuration pathways and
is effective when there is excess of methionine or
cysteine synthesis is required.

In 1990, the cut-off for homocysteine was
greater than 20µmole/L. This number
continued to go lower, and today, a level
somewhere around 12µmole/L is considered
as the recent cut-off. Homocysteine analyses
in The National Health and Nutrition
Examination Survey III (NHANES) results
shed some light into what constitutes ‘normal’
homocysteine levels in the US population.
A study conducted in 1999 by NHANES
investigators (published in Ann Intern Med
1999; 131:331) showed that homocysteine
levels continue to increase as a person ages, and men
have a higher mean concentration than women.
The AKUH Clinical Laboratory in Karachi, measures
the quantitative anticardiolipin IgG & IgM are
measured using the DIASTAT anti-cardiolipin kit by
indirect enzyme immunoassay method. The ACA panel
includes only IgG and IgM antibodies.The incidence of
IgA ACA is extremely low and their determination is
not helpful in the investigation of thrombosis or other
manifestations of the APLA syndrome.
15
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CD55 and CD59 for the Diagnosis of PNH
Fatima Azra Ausat
Haematology

Paroxysmal nocturnal hemoglobinuria (PNH)
is an acquired clonal hematopoietic stem cell
disorder induced by exposure to chemicals or
certain antibiotics and characterised by chronic
intravascular haemolysis, venous thrombosis,
defective haematopoiesis, frequent episodes of
infection and rarely, leukemic transformation.
Pathophysiology of PNH

Gel card tubes contain monoclonal antibodies
against CD55 and CD59; if cells express both
antigens the cells agglutinate by forming
antigen antibody complexes and bind the
mouse antibodies. After centrifugation through
the gel, cells carrying antibodies, confirming
the presence or MIRL or DAF, will show
a positive reaction, grade three-four in the
micro-tubes indicates the presence of a normal

Patients with PNH have a defective gene
called PIG-A, involved in the biosynthesis of
glycosylphosphatidylinositol (GPI).Without
GPI, important regulatory proteins (e.g. CD55
or “DAF” and CD59 “MIRL”) cannot bind to
the surface and protect blood cells from attacks
of various proteins called complements. This
may result in a breakdown of erythrocytes and
release of haemoglobin which causes the urine
to turn dark during an episode (or “paroxysm”)
of haemolysis, though this is not found in all
cases.
There are certain diagnostic tests which are
used in the diagnosis of PNH including Ham’s
test, sucrose lysis test, and CD55 and CD59
analysis by flow cytometry and by using gel
card technique.
CD55 and CD59 determination by gel card
technique
Gel agglutination assay for PNH is a simple
method for screening red cells for deficiency
of GPI linked protein. For optimal results,
the determination should be performed using
a freshly drawn blood sample preferably
into EDTA, citrate or heparin, CPD-A
anticoagulant.
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Fig. 1. Gel card showing results for a normal person (three gel tubes on the
left) and from a patient suffering from PNH (three gel tubes on the right)

cell population. Cells deficient in MIRL or
DAF show a negative reaction as a compact
button at the bottom of the micro tube [Fig.1].
Double population of cells indicates a weak
positive PNH test. Whenever it is necessary
to know the amount of cells affected, a
quantitative test procedure such as flow
cytometry should be performed following a
positive ID-PNH test.
PNH is only diagnosed where both MIRL and
DAF are shown to be deficient.
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Detection of Heparin/Platelet Factor 4 Antibodies
Safia Naz
Haematology

Heparin-induced thrombocytopenia (HIT) is the
development of thrombocytopenia due to the
administration of Heparin. HIT predisposes to
thrombosis and when thrombosis is identified
the condition is called “Heparin-induced
thrombocytopenia and thrombosis (HITT).” Clinical
features associated with HIT syndrome primarily
include a decreased platelet count, risk of venous
or arterial thromboembolic complication and the
development of antibodies against a complex of
heparin and PF4. HIT is a life and limb threatening
condition. The diagnosis is made on clinical suspicion
requiring laboratory confirmation. The testing is
recommended in all patients whose platelet count drop
by 50 per cent of baseline within three to five days
of heparin administration. HIT is observed both with
unfractionated heparin and with low molecular weight
heparin though the risk is less with latter.
Several tests are available for detection of Heparin/
PF4 antibodies in the laboratory [Table 1]. Aga
Khan University Hospital, Clinical Laboratory
uses ID-PaGIA Heparin/PF4 Antibody Gel Test for
detection of these antibodies against this complex.

The ID-PaGIA Heparin/PF4 antibody test is a particle
gel immuno assay (PaGIA). High density synthetic
polymer particles are coated with heparin/platelet
factor 4 complex (HPF4). When these particles are
mixed with patient serum-specific antibodies of any
immunoglobulin class, they react with the HPF4A on
the bead surface, causing agglutination. When the
reaction mixture is centrifuged through a gel filtration
matrix, agglutinated particles are trapped on top of
the gel or distributed within the gel (positive reaction)
while free or non- agglutinated particles form a pellet
at the bottom of the micro tube (negative reaction).
Due to the strong red colour of these particles, the
result can be read visually with ease [Fig.1].

Fig. 1. Heparin/HP4 Gel Card showing Negative results for Patient One
and Two and Positive results for Patient Three and Four.

Table 1. Recommendation for laboratory Testing for Heparin Induced Thrombocytopenia Antibodies

Test

Methodology

Particle gel immunoassay
ID-Heparin/PF4 antibody
test (ID-H/PF4)

Patient serum and PF4 heparin-coated micro-beads are added to the incubation
chamber of the micro-column card and after five minutes, the card is
centrifuged. A strong positive result indicated by the agglutinated micro-beads
remaining top of the column.

Enzyme linked
immunosorbent assay
test (ELISA)

It detects all circulating antibodies that bind Heparin PF4 complexes and may
also falsely identify antibodies that do not cause HIT. Therefore, ELISA is more
sensitive but less specific requiring further testing.

Platelet aggregation test

Citrated platelet rich-plasma is used as an initial test for HIT, a positive result
generally supports the diagnosis of HIT and further testing is not required.
However negative test does not exclude HIT in a patient with a moderate or
high pre-test probability for HIT. In this situation washed platelets activation
assay should be performed.

Serotonin release
assay/washed platelets
activation assays

SRA is considered to be gold standard and is specific for the HIT antibodies.
The platelets are washed and mixed with serum and heparin. The sample is then
tested for the release of serotonin, a marker of platelet activation. If serotonin
release assay shows high serotonin release, the diagnosis of HIT is confirmed.
17
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Anti-factor Xa Assay
Dr Natasha Ali
Haematology

Heparin is used widely for the prevention and
treatment of thromboembolic diseases, during
procedures of haemodialysis and cardiopulmonary
bypass surgeries. Two types of heparin preparations
widely in use today are unfractionated heparin (UFH)
and low molecular weight heparin (LMWH). The
inconvenience and limited precision of monitoring of
(UFH) therapy has contributed to the increasing use of
LMWH preparations. The pharmacokinetic properties
of LMWH are different from (UFH) and allows for
easily monitored anticoagulant effects of a given dose.
Monitoring is, however, recommended in clinical
settings like renal insufficiency, obesity, paediatric
patients and those on prophylactic anticoagulant
therapy in conditions like malignancy or antiphospholipid syndrome. Anti-factor Xa assay is used
to monitor LMWH therapy.

of LMWH. Blood sample should be delivered to the
laboratory immediately or else falsely low values
may occur (because platelets release platelet factor
4 (PF4) which can neutralise heparin or LMWH).
For the same reason, plasma must be separated from
cells as soon as possible, ideally within one hour of
specimen collection. Plasma can be stored for two
hours at room temperature or can be frozen for later
testing.
Laboratory is specifically notified as to which drug
should be measured (heparin, LMWH). Limitations
of this test include cost issues and less ready
availability than the activated partial thromboplastin
time (APTT) for heparin monitoring.
Table 1. Reference Ranges for Anti-Factor Xa

Principle of anti-factor Xa is based on the fact
that both factor Xa and antithrombin III are added
in excess amounts to the test plasma and the
residual factor Xa activity is inversely proportional
to the heparin concentration. The test is based
on the assumption that the patient has a normal
concentration of antithrombin III.

Heparin: 0.3-0.7 units/ml

The test is performed by adding a known amount
of factor Xa and antithrombin to the plasma of
the patient. If heparin or LMWH is present in the
patient plasma, it will bind to antithrombin and
inhibit factor Xa. The amount of residual factor Xa
is inversely proportional to the amount of heparin
in the plasma. The amount of residual factor Xa is
detected by adding a chromogenic substrate that
resembles the natural substrate of factor Xa. Factor
Xa cleaves the chromogenic substrate, releasing
a coloured compound that can be detected by
a spectrophotometer. Results are reported as
anticoagulant concentration in anti-factor Xa units/
ml, such that high anti-factor Xa values indicate
high levels of anticoagulation. Deficiencies of
antithrombin in the patient do not affect the assay,
because excess antithrombin is provided in the
reaction.

Target range for DVT prophylaxis (prevention):
There is no defined target range for prophylaxis
of deep vein thrombosis DVT because such
anticoagulation is not usually monitored. When
anti-Xa levels have been measured, mean
values are usually <0.45 units/ml.

Specimen is collected in sodium citrate bottle (blue
top) about four hours after subcutaneous injection
18

LMWH: 0.4-1.1 units/ml for twice daily
subcutaneous dosing. For once daily
subcutaneous LMWH dosing, the therapeutic
range is less certain but is approximately 1-2
units/ml.

Therapeutic range UFH: 0.3-0.7 U/L
Therapeutic range LMWH: 0.5-1.0 U/L
Prophylactic range UFH : 0.1-0.29 U/L
Prophylactic range LMWH: 0.20-0.49 U/L
Patients not on anticoagulants: 0 unit/ml.
Therapeutic range for anti-factor Xa for a deep
venous thrombosis (DVT) patient differs according
to the type of preparation used.:
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Causes of Sub-Therapeutic Anti-factor Xa Level
1. Specimen drawn at incorrect time (collection
times are four hours after injection of LMWH,
six hours after injection of danaparoid).
2. Specimen transportation time longer than two
hours.
3. Patient receiving prophylactic dose, therefore,
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therapeutic range is not applicable and anti-		
Xa level is actually appropriate for dose.
Causes of Supra Therapeutic Anti-factor Xa Level
1. Renal failure (with LMWH or danaparoid)
because of decreased renal clearance.
2. Heparin contamination, if specimen was
drawn from an IV heparinised line.
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